NRD
PCVX icon

Nebula Research & Development’s Vaxcyte PCVX Stock Holding History

Nebula Research & Development’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49,873
Closed -$1.62M – 637
2025
Q2 		$1.62M Buy
49,873
+1,113
+2% +$36.5K 0.14% 244
2025
Q1 		$1.84M Buy
+48,760
New +$3.9M 0.17% 187

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Nebula Research & Development's PCVX Position: Q3 2025 in Review

Nebula Research & Development sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 49,873 shares — an estimated $1.62M sold.

Nebula Research & Development first reported a position in PCVX in Q1 2025 and held it in 2 quarters. The position peaked at $1.84M in Q1 2025. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • Nebula Research & Development reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 49,873 Vaxcyte shares in Q3 2025, an estimated $1.62M.
  • Nebula Research & Development first reported a position in Vaxcyte in Q1 2025 and held it in 2 quarters.
  • Nebula Research & Development's Vaxcyte position peaked at $1.84M in Q1 2025.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.